Mesoblast Financial Results and Corporate Update Webcast
Rhea-AI Summary
Mesoblast (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, has announced a webcast to discuss its operational highlights and financial results for the full year ended June 30, 2024. The event is scheduled for Wednesday, August 28 at 6:30pm EDT (Thursday, August 29 at 8:30am AEST). Investors and interested parties can access the webcast through the provided link, with an archived version to be made available on the company's website afterward. This presentation is expected to offer insights into Mesoblast's performance and future outlook in the field of cellular medicines.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, MESO gained 0.16%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEW YORK, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and financial results for the full year ended June 30, 2024.
The webcast will begin at 6.30pm EDT, Wednesday, August 28; 8.30am AEST, Thursday, August 29, 2024. It can be accessed via: https://webcast.openbriefing.com/msb-fyr-2024/
The archived webcast will be available on the Investor page of the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates which respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast has a strong and extensive global intellectual property portfolio with protection extending through to at least 2041 in all major markets. The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast’s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | Media |
| Paul Hughes | BlueDot Media |
| T: +61 3 9639 6036 | Steve Dabkowski |
| E: investors@mesoblast.com | T: +61 419 880 486 |
| E: steve@bluedot.net.au |
FAQ
When is Mesoblast's financial results webcast for the full year ended June 30, 2024?
How can investors access Mesoblast's (MESO) financial results webcast?
What will be discussed in Mesoblast's (MESO) upcoming webcast?
Where can I find the archived version of Mesoblast's (MESO) financial results webcast?
